✦ LIBER ✦

Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions

✍ Scribed by Potiron, Vincent A.; Abderrhamani, Rym; Giang, Eric; Chiavassa, Sophie; Di Tomaso, Emmanuelle; Maira, Sauveur-Michel; Paris, François; Supiot, Stéphane

Book ID: 122757203
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 767 KB
Volume: 106
Category: Article
ISSN: 0167-8140
DOI: 10.1016/j.radonc.2012.11.014

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Corrigendum to “Radiosensitization of pr

Corrigendum to “Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions” [Radiother Oncol 106 (2013) 138–146]

✍ Potiron, Vincent A.; Abderrahmani, Rym; Giang, Eric; Chiavassa, Sophie; Di Tomas 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 158 KB

Inhibition of Autophagy as a Strategy to

Inhibition of Autophagy as a Strategy to Augment Radiosensitization by the Dual PI3K/mTOR Inhibitor NVP-BEZ235

✍ Maity, A.; Cerniglia, G.J.; Karar, J.; Koumenis, C. 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 54 KB

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor,

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

✍ Serra, V.; Markman, B.; Scaltriti, M.; Eichhorn, P. J.A.; Valero, V.; Guzman, M. 📂 Article 📅 2008 🏛 American Association for Cancer Research 🌐 English ⚖ 682 KB

673 ANTI-TUMOR EFFECT OF DUAL PI3K/MTOR

673 ANTI-TUMOR EFFECT OF DUAL PI3K/MTOR INHIBITOR NVP-BEZ235 AGAINST DOCETAXEL- AND HORMONE-RESISTANT HUMAN PROSTATE CANCER CELL LINE

✍ C.Y. Yoon; M.J. Park; S.W. Doo; H.Z. Park; D.S. Kim; W.K. Lee; S.H. Paick; S.J. 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 115 KB

Inhibition of DNA Double-Strand Break Re

Inhibition of DNA Double-Strand Break Repair by the Dual PI3K/mTOR Inhibitor NVP-BEZ235 as a Strategy for Radiosensitization of Glioblastoma

✍ Gil del Alcazar, C. R.; Hardebeck, M. C.; Mukherjee, B.; Tomimatsu, N.; Gao, X.; 📂 Article 📅 2013 🏛 American Association for Cancer Research 🌐 English ⚖ 446 KB

The efficacy of a novel, dual PI3K/mTOR

The efficacy of a novel, dual PI3K/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer

✍ Niranjan Awasthi; Peter L. Yen; Margaret A. Schwarz; Roderich E. Schwarz 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 419 KB

## Abstract Gemcitabine has limited clinical benefits for pancreatic ductal adenocarcinoma (PDAC). The phosphatidylinositol‐3‐kinase (PI3K)/AKT and mammalian target of rapamycin (mTOR) signaling pathways are frequently dysregulated in PDAC. We investigated the effects of NVP‐BEZ235, a novel dual PI